AI agents, Meta's $567M order, and Lilly's GLP-1 fights: Litigation Tracker — Week of August 4
Six material litigation developments from August 4–10, 2026, spanning AI trade secrets and agent access, platform youth-safety remedies, LinkedIn antitrust discovery, and Lilly's GLP-1 competition and patent fights.
Coverage window: August 4–10, 2026. Six developments made the cut: two AI disputes over trade secrets and agent access, two platform cases that move from discovery to product-design remedies, and two pharma cases that draw different lines around competition and generic entry. The common question is practical: who controls the interface, information, or distribution channel when a business model becomes legally contested?
At a glance
| Case | Sector | Current stage | Why it matters | Next milestone |
|---|---|---|---|---|
| Apple v. OpenAI | AI / trade secrets | OpenAI moved to dismiss; Apple's injunction and expedited-discovery requests are pending | Tests how quickly trade-secret claims tied to AI hardware can reach internal product and recruiting evidence | Rulings on dismissal, injunction, and expedited discovery; date not public 12 |
| Amazon v. Perplexity | AI / platform access | Ninth Circuit vacated the preliminary injunction against Perplexity | Narrows an early computer-access theory against an AI shopping agent while the merits case continues | Proceedings in the district court; Amazon said it was evaluating its next steps 3 |
| Crowder et al. v. LinkedIn Corp. | Tech / antitrust | Discovery expanded to permit depositions of two senior executives | Puts market-power and premium-pricing allegations under executive scrutiny; class certification is unresolved | Class-certification decision by Judge Haywood Gilliam Jr.; date not public 4 |
| New Mexico v. Meta Platforms | Tech / consumer protection | Bench-trial judgment: $567 million fund plus five years of youth-safety measures | Treats platform design and AI-chatbot safeguards as part of a public-nuisance remedy, subject to appeal | Meta's appeal; date not public 56 |
| Strive Specialties v. Eli Lilly and Novo Nordisk | Pharma / antitrust | W.D. Tex. dismissed the complaint | Shows how product-market definition can end a challenge to contracting around compounded GLP-1 drugs at the pleading stage | Strive is evaluating an appeal; date not public 7 |
| Eli Lilly's tirzepatide generic actions | Pharma / patent | Multiple Delaware patent suits filed against generic makers | Opens a new generic-entry fight around nine asserted patents and a large group of potential entrants | Case-specific scheduling orders or responses; not publicly reported 8 |
AI sector cases
Apple v. OpenAI: trade-secret claims now have two procedural fronts
Parties. Apple is suing OpenAI and two former Apple employees, Chang Liu and Tang Yew Tan. Reuters also identified io Products in the case. The dispute is in the U.S. District Court for the Northern District of California; a docket number was not reported. 1
Claims. Apple alleges that OpenAI and the former employees misappropriated confidential information to help OpenAI move into consumer hardware. Apple says the alleged theft involved information obtained through recruiting and supplier relationships. Those are allegations, not findings on the merits. 1
Current stage. Apple asked for a preliminary injunction barring access to, use of, or disclosure of the alleged secrets, and sought expedited discovery and depositions. OpenAI then moved to dismiss, arguing that Apple had not identified protectable trade secrets with enough specificity or plausibly alleged misappropriation. Reuters published the dismissal report on August 6; no ruling on either request was reported. 2
Business impact. The fight reaches beyond a single employee departure. If the court permits fast discovery, Apple may seek internal records about recruiting, supplier contacts, access controls, and product planning before the case reaches a merits hearing. Companies building AI hardware will need to preserve those records and show that confidential design knowledge is separated from ordinary industry know-how.
Precedent value. The immediate signal is procedural, not a ruling that Apple owns the information or that OpenAI used it. The important question is whether a court will let a trade-secret plaintiff investigate a fast-moving AI product strategy when the defendant says the alleged categories are too general to be legally protected. A decision allowing discovery would lower the practical threshold for testing those allegations; dismissal would push plaintiffs toward more granular descriptions of the secret and the alleged use.
Next milestone. The court's decisions on OpenAI's motion to dismiss, Apple's preliminary-injunction request, and expedited discovery are next. No date was publicly reported. 2
Amazon v. Perplexity: the Ninth Circuit lifts the first block on an AI shopping agent
Parties. Amazon sued Perplexity AI over the startup's Comet browser and AI shopping tools. The Ninth Circuit heard the appeal; the public reports reviewed here did not provide a docket number. 3
Claims. Amazon alleges that Perplexity's agent covertly accessed private customer accounts and Amazon's computers without permission, violating the federal Computer Fraud and Abuse Act and creating security risks. Perplexity disputes the theory. The merits allegations remain unresolved. 3
Current stage. On August 4, the Ninth Circuit vacated a March preliminary injunction that had barred Perplexity's agent from making purchases for users on Amazon's platform. The court said Amazon was unlikely to prevail on the argument that the AI tool itself had "accessed" Amazon's servers under the hacking statute; the court favored Perplexity's position that the users, rather than the agent, were the relevant actors for that statutory element. 39
Business impact. The ruling removes an immediate injunction but does not give AI agents a general license to automate purchases. Platform operators still control contracts, authentication, account security, and other possible claims. Agent developers, meanwhile, have a stronger argument against treating an automated user action as unauthorized computer access without a closer showing about who actually entered the system.
Precedent value. The case is an early appellate marker for the legal boundary between a user-directed agent and the company that built it. The Ninth Circuit's preliminary assessment is narrower than a final rule on agent liability: it addressed Amazon's likelihood of success on one access theory, not every claim that might arise from automated shopping, data collection, or account activity.
Next milestone. The case returns to the district court with the preliminary injunction lifted. Amazon said it was evaluating its next steps; no further hearing date was publicly reported. 3
Tech-platform cases
Crowder et al. v. LinkedIn: executive testimony enters the antitrust record
Parties. Todd Crowder and other plaintiffs are suing LinkedIn Corp. in the U.S. District Court for the Northern District of California. Magistrate Judge Laurel Beeler issued the discovery ruling; Reuters did not report a docket number. Microsoft is not a defendant in the account of this case. 4
Claims. The complaint alleges that LinkedIn controls more than 97% of the professional social-networking market and uses that position to charge excessive prices for premium subscriptions. The plaintiffs' allegations are still to be tested; the class-certification question remains open. 4
Current stage. On August 5, Judge Beeler allowed the plaintiffs to depose current CEO Daniel Shapero for four hours and former CEO and co-founder Reid Hoffman for three hours. The order expands discovery. It does not decide whether LinkedIn monopolized the market, whether its pricing was unlawful, or whether the case can proceed as a class action. 4
Business impact. Executive testimony can expose how a platform defines its market, sets premium prices, and responds to competitive pressure. For subscription platforms, the risk is not limited to a damages number: discovery can turn product strategy, pricing experiments, and internal market-share analysis into evidence available to follow-on claimants.
Precedent value. The immediate legal signal is about the scope of antitrust discovery. Allowing the depositions suggests the plaintiffs have tied senior-executive testimony to issues the court considers material, but it says nothing about the merits. The eventual ruling on market definition and class certification will matter more for other subscription and professional-networking platforms.
Next milestone. U.S. District Judge Haywood Gilliam Jr. must decide whether the case may proceed as a class action. No date was publicly reported. 4
New Mexico v. Meta: a public-nuisance judgment reaches platform design and AI chatbots
Parties. New Mexico Attorney General Raúl Torrez sued Meta Platforms in Santa Fe County court. Judge Bryan Biedscheid issued the bench-trial judgment; a docket number was not reported. 5
Claims. The state pursued a public-nuisance theory over the effects of Meta's platforms on children, alongside earlier claims under New Mexico's Unfair Practices Act. The second phase focused on abatement: what the court could require to address the alleged harm. 6
Current stage. On August 6, the court found that Meta had created or substantially contributed to a public nuisance in New Mexico. It ordered Meta to pay $567 million into a teen mental-health fund and to implement youth-safety measures for five years, including limits on teen use and notifications, tighter controls on adult contact with minors, safeguards for AI chatbots, and stronger review of child-sexual-abuse reports. The fund is separate from the $375 million in civil penalties ordered after an earlier jury phase. 56
The court rejected Meta's Section 230 defense as to the state's platform-design theory, according to Reuters, and some requested remedies were denied because of First Amendment concerns, Section 230 limits, or practical effects on competition. Meta said it would appeal. 5
Business impact. This is a product-design order, not just a damages award. The court directed changes to how young users interact with Meta's services and how the company constrains AI-chatbot interactions. Other platforms will watch whether similar state theories can reach recommender systems, engagement features, age controls, and chatbot guardrails without being treated as claims about third-party speech.
Precedent value. The judgment gives state attorneys general a concrete model for pairing consumer-protection claims with public-nuisance abatement. Its reach is uncertain because it is a state trial-court ruling and Meta plans to appeal. The appellate question is likely to be as important as the factual findings: how far a state may regulate platform architecture through nuisance remedies, and where Section 230 or the First Amendment cuts off that remedy.
Next milestone. Meta's appeal is the next public milestone. The reports did not provide a briefing schedule or hearing date. 5
Pharma and biotech cases
Strive Specialties v. Eli Lilly and Novo Nordisk: the GLP-1 antitrust case fails on market definition
Parties. Strive Specialties Inc., a compounding pharmacy, sued Eli Lilly and Novo Nordisk in the U.S. District Court for the Western District of Texas in San Antonio. The accessible reports did not provide a docket number. 7
Claims. Strive alleged that Lilly and Novo entered exclusive deals with major telehealth providers that kept doctors on those platforms from prescribing compounded GLP-1 drugs. The theory was that the arrangements limited physician and patient choice and suppressed competition. 7
Current stage. On August 6, Judge Micaela Alvarez dismissed the lawsuit. The court held that Strive had not plausibly defined a product market because compounded GLP-1 drugs are available when a physician decides a branded drug cannot meet a patient's specific medical needs; on that account, the two categories were not reasonably interchangeable. The judge also found that Strive had not adequately shown antitrust harm, emphasizing that antitrust law protects competition rather than an individual competitor. 7
Business impact. A contracting strategy can be difficult to challenge if the plaintiff cannot show that compounded and branded products compete in the same legally relevant market. The ruling gives drugmakers and telehealth partners a reason to document the clinical and regulatory differences they rely on when structuring distribution agreements. It does not answer whether a different complaint, with a different market definition or evidence of exclusion, could survive.
Precedent value. The case is a useful pleading-stage signal for disputes over compounded versions of branded medicines. It narrows this plaintiff's route to an antitrust claim, but it is not a general holding that exclusive telehealth arrangements are lawful. Future cases will turn on product interchangeability, the actual contracting terms, and evidence of harm to competition.
Next milestone. Strive said it was evaluating options, including an appeal. No appeal date was publicly reported. 7
Eli Lilly's tirzepatide patent actions: generic entry meets nine asserted patents
Parties. Eli Lilly filed multiple lawsuits in the U.S. District Court for the District of Delaware against generic manufacturers. Law360 named Sandoz, MSN Laboratories, Eugia, Macleods, Rio, Zydus, Alembic, Biocon, Amneal, Dr. Reddy's, Hikma, Hybio, Aspiro, and Galenicum among the targets. The accessible report did not provide case captions or docket numbers for the individual actions. 8
Claims. The new actions seek to block generic versions of Lilly's tirzepatide medicines for weight loss and diabetes. Law360 listed nine asserted patents: 9,474,780; 11,357,820; 11,918,623; 12,295,987; 12,343,382; 12,453,755; 12,453,756; 12,453,758; and 12,616,740. The report did not state the individual defendants' patent certifications or identify specific generic product brands. 8
Current stage. The suits were filed on August 7. No validity, infringement, or claim-construction ruling has been reported. This is an entry-stage patent fight, not a decision that the patents will block generic competition.
Business impact. Filing against a large group of potential entrants can increase the number of launch dates that depend on patent outcomes. For Lilly, the immediate value is preserving a litigation route around a major revenue product. For generic manufacturers and investors, the relevant work is case-by-case: identify which patents each defendant challenges, which claims cover the product, and whether the court sets coordinated schedules.
Precedent value. There is no precedent yet in the filing itself. The later claim-construction, validity, and infringement rulings could affect how pharmaceutical companies layer patents around a single active ingredient and how generic entrants price the risk of launch. Until those rulings arrive, the signal is exposure and timing rather than a new legal standard.
Next milestone. The accessible report did not state the first hearings, responses, or case-management dates. Those milestones are not publicly reported in the source. 8
Cases to watch
- Apple v. OpenAI. Watch whether the court permits expedited discovery before deciding whether Apple's description of the alleged secrets is specific enough. The answer will shape the cost of defending AI hardware trade-secret claims. 1
- Amazon v. Perplexity. The district court's next ruling will show whether Amazon can shift from the unsuccessful computer-access theory to contract, security, or other claims after the Ninth Circuit lifted the injunction. 3
- New Mexico v. Meta. The appeal will test whether public-nuisance abatement can require changes to recommender systems, youth controls, and AI-chatbot behavior. 5
- Crowder v. LinkedIn. The class-certification decision is the next checkpoint for whether the alleged 97% market share and premium pricing can be litigated on behalf of a broader customer group. 4
- Strive v. Lilly/Novo. An appeal or amended complaint would reveal whether Strive changes its product-market theory or adds evidence about telehealth exclusivity and compounded-drug substitution. 7
- Lilly's tirzepatide actions. The first defense filings and any coordinated scheduling order will identify which of the nine patents and which generic-entry theories will drive the litigation. 8
The immediate risk signal is uneven: Meta has already received a broad trial-court remedy, Amazon has lost an early injunction, and Lilly's generic cases have not yet produced a ruling. The next edition will turn on which of those procedural differences becomes a merits signal.
References
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.